- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05579769
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
The participants are being asked to take part in this clinical trial because the participant have a lymphoid or myeloid based cancer diagnosis that requires a bone marrow transplant.
Primary Objectives
To estimate the incidence of severe acute GVHD (saGVHD) using a prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic Human Leukocyte antigen (HLA)-matched sibling or unrelated donor HCT for hematological malignancies.
Secondary objective
Determine the cumulative incidence of relapse, NRM, chronic GVHD, and OS in study participants at one year post-transplant.
Exploratory objectives
- To evaluate the pharmacokinetic/pharmacodynamic (PK/PD) profiles of ruxolitinib, fludarabine, and rATG.
- To assess immune reconstitution in study participants within the first year post-HCT.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ashok Srinivasan, MD
- Phone Number: 866-278-5833
- Email: referralinfo@stjude.org
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- Recruiting
- St. Jude Children's Research Hospital
-
Contact:
- Ashok Srinivasan, MD
- Phone Number: 866-278-5833
- Email: referralinfo@stjude.org
-
Principal Investigator:
- Ashok Srinivasan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
Diagnosis:
- Patients with high risk acute lymphoblastic leukemia in first remission. Examples include, but are not limited to, patients with certain leukemic cell cytogenetic findings (e.g. t(9;22) or t(4;11)); delayed response to induction chemotherapy; re-emergence of leukemic blasts by MRD (at any level) in patients previously MRD negative; persistently detectable MRD at lower levels; early T-cell precursor (ETP) ALL.
- Patients with acute lymphoblastic leukemia beyond first remission.
- Patients with Hodgkin's disease beyond first remission or with refractory disease.
- Patients with chronic myelogenous leukemia.
- Patients with primary or secondary myelodysplastic syndrome.
- Patients with Non-Hodgkin's lymphoma beyond first remission or with refractory disease.
- Patients with de novo acute myeloid leukemia in or beyond first remission or with relapsed or refractory disease, or myeloid sarcoma (extra-medullary AML).
- Patients with secondary acute myeloid leukemia.
- NK cell lymphoblastic leukemia in any CR.
- Biphenotypic, bilineage, or undifferentiated leukemia.
- Juvenile Myelomonocytic Leukemia (JMML)
- All patients with prior evidence of CNS leukemia must be treated and be in CNS CR.
Patients must have a related or unrelated donor matched at 12 of 12 HLA alleles.
Patient must have a Karnofsky/Lansky score of 70 or higher.
Patients must be 12 years of age or older.
Patients must have a shortening fraction >26% or left ventricular ejection fraction >40%.
Patients must have bilirubin less than or equal to 2.5 mg/dL and alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal.
Patients must have creatinine clearance, or a glomerular filtration rate (GFR), greater than 70 mL/min/1.73m2.
Patients must be free of severe infection that upon determination of principal investigator precludes BMT.
Patients must have FVC >50% predicted OR, if unable to perform pulmonary function testing, must maintain pulse oximetry oxygen saturation >92% on room air.
Female patients of childbearing age must have a negative pregnancy test.
Exclusion criteria
- Patients who have undergone prior HCT.
- Patients who have a peripheral blood stem cell graft source.
- Patients who have a non-permissive mismatch at the DPB1 allele.
- Patients who are HIV positive.
- Patients positive for Hepatitis B surface antigen (HBsAg).
- Patients positive for Hepatitis C.
- Patients with latent tuberculosis with positive TB IFN gamma release assay.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ArmA- Lymphoid
Total Body Irradiation and cyclophosphamide (TBI/Cy)
|
Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
Other Names:
Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
Other Names:
Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
Other Names:
Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
Other Names:
Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
Other Names:
Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons. Dose rate should be < 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor. Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose. An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia.
Other Names:
Day 0
|
Active Comparator: ArmB-Myeloid
TBF with comparable NRM in comparison to busulfan and cyclophosphamide (BuCy)
|
Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
Other Names:
Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
Other Names:
Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
Other Names:
Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
Day 0
Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
Other Names:
Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
Other Names:
Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of severe acute GVHD (saGVHD) using a prophylaxis regimen with no calcineurin inhibitors after day 100 post first allogeneic Human Leukocyte antigen (HLA)-matched sibling or unrelated donor HCT for hematological malignancies.
Time Frame: 100 days post transplant
|
Development of saGVHD at or before Day 100 post transplant is considered as an event.
|
100 days post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Leukemic Relapse
Time Frame: One-year post-transplantation.
|
Bone marrow studies for disease status evaluation will be performed.
|
One-year post-transplantation.
|
Non-relapse mortality
Time Frame: One-year post-transplantation
|
The one-year non-relapse mortality (NRM is defined by the patient who expire while in remission within one year.
The probability of NRM is estimated by the cumulative incidence method.
|
One-year post-transplantation
|
Overall Survival
Time Frame: one year post-transplantation
|
The one-year survival is defined by the patient who has not died within one year after post transplantation.
The probability is estimated by the Kaplan-Meier method.
|
one year post-transplantation
|
Incidence of Chronic Graft Versus Host Disease (cGVHD)
Time Frame: 1 year post transplant
|
Ongoing assessment of toxicity will be done using the NCI CTCAE version 3.0.
Acute and chronic graft-vs.-host
disease will be evaluated using the standard grading criteria.
The cumulative incidence of cGvHD will be estimated using Kalbfleisch-Prentice method.
|
1 year post transplant
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Site
- Hematologic Diseases
- Neoplasms
- Hematologic Neoplasms
- Graft vs Host Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dermatologic Agents
- Antifungal Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Calcineurin Inhibitors
- Cyclophosphamide
- Fludarabine
- Methotrexate
- Thiotepa
- Busulfan
- Thymoglobulin
- Antilymphocyte Serum
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- CNI60
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
CRISPR Therapeutics AGEnrolling by invitationHematologic Malignancy | Solid MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
Clinical Trials on Ruxolitinib
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Bronchiolitis Obliterans SyndromeChina
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Julie NangiaIncyte Corporation; Translational Breast Cancer Research ConsortiumRecruitingDuctal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In SituUnited States
-
Incyte CorporationActive, not recruiting
-
Beijing Friendship HospitalUnknownHemophagocytic LymphohistiocytosisChina
-
Children's Hospital Medical Center, CincinnatiRecruitingBronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)United States
-
University of JenaCompleted
-
University of Michigan Rogel Cancer CenterCompletedHemophagocytic Syndrome (HPS)United States
-
Margherita MaffioliUnknown
-
University of PittsburghWithdrawnHead and Neck Squamous Cell Carcinoma